Atara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 Shares

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of the business’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $14.25, for a total transaction of $62,700.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) traded down $0.30 during trading hours on Tuesday, hitting $14.50. 346,300 shares of the company were exchanged, compared to its average volume of 229,167. Atara Biotherapeutics, Inc. has a twelve month low of $11.80 and a twelve month high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.05). research analysts expect that Atara Biotherapeutics, Inc. will post -4 earnings per share for the current year.

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in Atara Biotherapeutics in the 3rd quarter valued at approximately $142,000. Russell Investments Group Ltd. bought a new position in Atara Biotherapeutics during the 3rd quarter valued at about $170,000. Voya Investment Management LLC grew its position in shares of Atara Biotherapeutics by 16.2% during the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after buying an additional 1,651 shares during the period. State of Wisconsin Investment Board bought a new position in Atara Biotherapeutics during the 2nd quarter worth approximately $252,000. Finally, The Manufacturers Life Insurance Company boosted its stake in Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares during the last quarter. Institutional investors and hedge funds own 85.61% of the company’s stock.

Several analysts have recently issued reports on ATRA shares. BidaskClub cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective on the stock in a report on Tuesday, August 22nd. Jefferies Group restated a “buy” rating and issued a $30.00 target price on shares of Atara Biotherapeutics in a research note on Thursday, August 31st. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Canaccord Genuity restated a “buy” rating and issued a $47.00 target price on shares of Atara Biotherapeutics in a research note on Monday, September 11th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. Atara Biotherapeutics presently has a consensus rating of “Hold” and an average price target of $24.40.

TRADEMARK VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (ATRA) CEO Isaac E. Ciechanover Sells 4,400 Shares” was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://ledgergazette.com/2017/12/12/atara-biotherapeutics-inc-atra-ceo-isaac-e-ciechanover-sells-4400-shares-2.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply